Connor Clark & Lunn Investment Management Ltd. Buys Shares of 41,386 DaVita Inc. $DVA

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of DaVita Inc. (NYSE:DVA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 41,386 shares of the company’s stock, valued at approximately $9,208,000. Connor Clark & Lunn Investment Management Ltd. owned 0.06% of DaVita as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in DVA. Value Investment Professionals LLC boosted its stake in shares of DaVita by 2.0% during the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after purchasing an additional 50 shares during the period. Kesler Norman & Wride LLC lifted its holdings in DaVita by 0.8% during the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after buying an additional 55 shares in the last quarter. Gen Wealth Partners Inc lifted its holdings in DaVita by 10.0% during the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after buying an additional 80 shares in the last quarter. NewEdge Advisors LLC boosted its position in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the period. Finally, Orion Porfolio Solutions LLC grew its stake in DaVita by 4.4% in the 4th quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock worth $268,000 after acquiring an additional 99 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Up 1.4%

Shares of DVA stock opened at $180.34 on Thursday. The firm has a market cap of $11.51 billion, a price-to-earnings ratio of 14.76, a PEG ratio of 0.59 and a beta of 0.88. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The company’s 50 day moving average is $213.07 and its 200 day moving average is $182.80.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same quarter in the prior year, the business earned $2.95 earnings per share. DaVita’s revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts anticipate that DaVita Inc. will post 14.57 EPS for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DVA. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Oppenheimer set a $220.00 target price on DaVita in a research report on Friday, August 7th. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 price target on shares of DaVita in a research note on Wednesday, August 5th. Finally, Truist Financial decreased their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, DaVita presently has an average rating of “Hold” and a consensus target price of $221.75.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.